Literature DB >> 24009048

Using the stated preference technique for eliciting valuations: the role of the payment vehicle.

Dorte Gyrd-Hansen1.   

Abstract

At the core of the stated preference method is choice of payment vehicle. Since payment vehicle is an intrinsic characteristic of a good, the choice of payment vehicle will naturally impact on the valuation of the good. Typical payment vehicles applied in the context of health are income tax levies, out-of-pocket payments at the point of consumption or private health insurance premiums. Where out-of-pocket payments will elicit use value only, private health insurance premiums will also disclose option value, i.e. the utility of knowing that one has access to a healthcare service should one need it. Income tax levies will disclose what in this paper is referred to as citizen's preferences, i.e. individual preferences that include use value, option value as well as (caring) externalities. This paper advocates that researchers design stated preference studies that encompass all relevant dimensions of value, and that serious thought is given to choice of payment vehicle. However, it is important to acknowledge that choice of payment vehicle has other potential implications for valuations. Payment vehicle and provider of services may be strongly linked in people's minds. If respondents implicitly associate a specific type of provider with a certain type of payment vehicle, it is important that any misperception is corrected by way of a precise description of the good being valued. Further, a pertinent issue is the extent to which respondents 'protest' to the stated preference question and how we should deal with these 'protesters'. No agreement currently exists about the procedure used to separate genuine zero values from protest values, nor about the treatment of protest responses in subsequent analyses. Beliefs are strongly associated with protesting, and exclusion of protest bids may therefore exclude individuals who have strong preferences for a payment vehicle. If it is acknowledged that payment vehicle is an intrinsic component of a good, exclusion of respondents who exhibit specific viewpoints may result in biased welfare estimates. Yet another issue is the presence of self-consciousness amongst respondents. If people derive utility from saying they are willing to pay for a public good (social desirability bias or warm glow), this potentially drives a wedge between people's stated value for a good in a survey and people's value for a good provided to them from the government. Tax payments are more binding than out-of-pocket payments. Payment towards public health programs via income tax may therefore generate lower consumer surplus than if the intervention was financed out-of-pocket with the option of opting out both in terms of participation as well as financially. Finally, only a few studies have looked at the impact of frequency of payments. The effect of temporal framing is clearly potentially important and at the same time an unavoidable component of the payment vehicle, yet it remains at present unexplored.

Entities:  

Mesh:

Year:  2013        PMID: 24009048     DOI: 10.1007/s40273-013-0086-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Uncertainty and the welfare economics of medical care. 1963.

Authors:  K J Arrow
Journal:  J Health Polit Policy Law       Date:  2001-10       Impact factor: 2.265

2.  Evidence of range bias in contingent valuation payment scales.

Authors:  David K Whynes; Jane L Wolstenholme; Emma Frew
Journal:  Health Econ       Date:  2004-02       Impact factor: 3.046

3.  An inquiry into the different perspectives that can be used when eliciting preferences in health.

Authors:  Paul Dolan; Jan Abel Olsen; Paul Menzel; Jeff Richardson
Journal:  Health Econ       Date:  2003-07       Impact factor: 3.046

Review 4.  Willingness to pay for antihypertensive therapy--further results.

Authors:  M Johannesson; P O Johansson; B Kriström; U G Gerdtham
Journal:  J Health Econ       Date:  1993-04       Impact factor: 3.883

5.  Willingness to pay for private and public road safety in stated preference studies: why the difference?

Authors:  Mikael Svensson; Maria Vredin Johansson
Journal:  Accid Anal Prev       Date:  2010-02-18

6.  Use, option and externality values: are contingent valuation studies in health care mis-specified?

Authors:  Richard D Smith
Journal:  Health Econ       Date:  2007-08       Impact factor: 3.046

7.  Welfarism vs. extra-welfarism.

Authors:  Werner B F Brouwer; Anthony J Culyer; N Job A van Exel; Frans F H Rutten
Journal:  J Health Econ       Date:  2007-11-29       Impact factor: 3.883

Review 8.  When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care.

Authors:  B O'Brien; A Gafni
Journal:  Med Decis Making       Date:  1996 Jul-Sep       Impact factor: 2.583

9.  Willingness to pay for reduced incontinence symptoms.

Authors:  M Johannesson; R M O'Conor; G Kobelt-Nguyen; A Mattiasson
Journal:  Br J Urol       Date:  1997-10

Review 10.  Perception and misperception of bias in human judgment.

Authors:  Emily Pronin
Journal:  Trends Cogn Sci       Date:  2006-11-28       Impact factor: 20.229

View more
  3 in total

1.  Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Authors:  J Jaime Caro; John E Brazier; Jonathan Karnon; Peter Kolominsky-Rabas; Alistair J McGuire; Erik Nord; Michael Schlander
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

2.  Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Woojung Lee; William B Wong; Stacey Kowal; Louis P Garrison; David L Veenstra; Meng Li
Journal:  Pharmacoeconomics       Date:  2022-05-09       Impact factor: 4.558

3.  Valuing Mobile Health: An Open-Ended Contingent Valuation Survey of a National Digital Health Program.

Authors:  Camilla Somers; Eleanor Grieve; Marilyn Lennon; Matt-Mouley Bouamrane; Frances S Mair; Emma McIntosh
Journal:  JMIR Mhealth Uhealth       Date:  2019-01-17       Impact factor: 4.773

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.